LIVE
BMRN
BioMarin Pharmaceutical Inc. · Healthcare
$54.69
+9.80% this month
VERSUS
⟷
COMPARE
ALNY
Alnylam Pharmaceuticals, Inc. · Healthcare
$278.09
-5.51% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
BMRN
3
ALNY
1
Comparison scoreboard
BMRN LEADS 3/5AI Score
BMRN 26.8
ALNY ✓57.2
1Y Return
BMRN ✓-1.00%
ALNY -10.96%
Fwd P/E
BMRN ✓8.46
ALNY 20.20
Target Up.
BMRN ✓+60.63%
ALNY +56.90%
Op. Margin
BMRN N/A
ALNY N/A
Metrics last refreshed: 6/20/2026
Quick take
BMRN vs ALNY Stock Comparison: AI Score, Valuation, Performance and Upside
BioMarin and Alnylam are both rare disease biopharmaceutical companies with distinct therapeutic modalities and commercial drug portfolios. BioMarin specializes in enzyme replacement therapies for metabolic genetic disorders; Alnylam uses RNA interference to silence disease-causing genes. Both are investing in gene therapy and platform expansion, though at different stages of commercial scale and profitability.
BMRN vs ALNY compares a rare disease ERT incumbent with gene therapy ambitions (BioMarin) against the RNAi platform pioneer building toward profitability on a novel drug modality (Alnylam) — BioMarin offers more current profitability, while Alnylam offers more platform technology upside if RNAi extends into large common disease markets.
Live analysis · updated 6/20/2026
BMRN holds the edge across 3 of 5 key metrics in this comparison. BMRN leads on both 1-year return (-1.00%) and forward P/E (8.46x vs 20.20x for ALNY), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for BMRN (+60.63%) than for ALNY (+56.90%).
Normalized 1Y performance
BMRN
ALNY
Recent returns
BMRN
ALNY
Analyst price targets & sentiment
BMRN · 26 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.7/5.0)
Price target range
analyst low$50.00
analyst high$120.00
analyst mean$87.85
current price$54.69
+60.6% upside to analyst mean
ALNY · 25 analysts
STRONG BUYHOLDSTRONG SELL
Buy (1.8/5.0)
Price target range
analyst low$310.00
analyst high$550.00
analyst mean$436.32
current price$278.09
+56.9% upside to analyst mean
Who should consider this stock?
BMRN may suit investors who:
- →prefer a profitable rare disease company with multiple commercial ERT products and deep lysosomal storage disorder expertise
- →value Voxzogo achondroplasia as a growing pediatric rare disease franchise independent of legacy ERT revenues
- →want more immediate profitability from rare disease investing vs Alnylam's earlier profitability timeline
- →are comfortable with Roctavian gene therapy commercial challenges and limited organic ERT growth requiring pipeline reinvestment
ALNY may suit investors who:
- →prefer the RNAi pioneer platform with potential to address genetic and common diseases through gene silencing
- →value Amvuttra's growing hATTR franchise and Leqvio cardiovascular partnership as two distinct commercial vectors
- →want platform technology upside if RNAi programs in hypertension and complement achieve late-stage clinical success
- →are comfortable with delayed GAAP profitability as Alnylam invests in pipeline and Amvuttra commercial scale
Performance & AI score
| Metric | BMRN | ALNY |
|---|---|---|
| AI score | 26.8 | 57.2 |
| AI rank | #2560 | #219 |
| Latest close | $54.69 | $278.09 |
| 1M return | +9.80% | -5.51% |
| 6M return | +5.58% | -29.08% |
| 1Y return | -1.00% | -10.96% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BMRN | ALNY |
|---|---|---|
| 1Y ago | $9.9K (-1.0%) started 2025-06-18 | $8.9K (-11.0%) started 2025-06-18 |
| 5Y ago | $6.68K (-33.2%) started 2021-06-18 | $15.72K (+57.2%) started 2021-06-18 |
| 10Y ago | $6.51K (-34.9%) started 2016-06-20 | $49.1K (+391.0%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | BMRN | ALNY |
|---|---|---|
| Market cap | $10.57B | $37.13B |
| Trailing P/E | 39.35 | 70.05 |
| Forward P/E | 8.46 | 20.20 |
| Price/Sales | 3.26 | 8.66 |
| EV/Revenue | 3.04 | 8.77 |
| Analyst target | $87.85 | $436.32 |
| Target upside | +60.63% | +56.90% |
Growth, profitability & risk
| Metric | BMRN | ALNY |
|---|---|---|
| Revenue growth | 2.80% | 96.40% |
| Earnings growth | -43.10% | N/A |
| EPS growth | -43.10% | N/A |
| FCF margin | +14.17% | +4.78% |
| Operating margin | N/A | N/A |
| Profit margin | 8.29% | 12.55% |
| ROIC proxy | 4.48% | 90.36% |
| Return on equity | 4.48% | 90.36% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 0.24 | 0.27 |
| Debt/equity | 23.17 | 276.20 |
| Current ratio | 5.81 | 3.13 |
| Quick ratio | 3.94 | 2.88 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
BMRN max drawdown22.49%
ALNY max drawdown43.39%
BMRN max wkly drop8.75%
ALNY max wkly drop14.54%
5Y risk snapshot
BMRN max drawdown57.64%
ALNY max drawdown43.39%
BMRN max wkly drop17.74%
ALNY max wkly drop20.65%
10Y risk snapshot
BMRN max drawdown62.09%
ALNY max drawdown59.95%
BMRN max wkly drop38.91%
ALNY max wkly drop49.44%
Performance metrics by period
| Period | Metric | BMRN | ALNY |
|---|---|---|---|
| 1Y | Growth | -1.00% | -10.96% |
| CAGR | -1.00% | -10.97% | |
| Sharpe ratio | 0.01 | -0.25 | |
| Max drawdown | 22.49% | 43.39% | |
| Max daily drop | 4.35% | 6.87% | |
| Max wkly drop | 8.75% | 14.54% | |
| 5Y | Growth | -33.22% | +57.21% |
| CAGR | -7.76% | +9.47% | |
| Sharpe ratio | -0.22 | 0.32 | |
| Max drawdown | 57.64% | 43.39% | |
| Max daily drop | 17.71% | 17.10% | |
| Max wkly drop | 17.74% | 20.65% | |
| 10Y | Growth | -34.94% | +390.98% |
| CAGR | -4.21% | +17.26% | |
| Sharpe ratio | -0.07 | 0.48 | |
| Max drawdown | 62.09% | 59.95% | |
| Max daily drop | 35.28% | 48.49% | |
| Max wkly drop | 38.91% | 49.44% |
Business comparison
| Category | BMRN | ALNY |
|---|---|---|
| Company | BioMarin Pharmaceutical Inc. | Alnylam Pharmaceuticals, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | N/A | N/A |
| Core business | BioMarin is a rare disease biopharmaceutical company specializing in enzyme replacement therapy (ERT) and gene therapy for genetic disorders. Its commercial portfolio includes Vimizim (MPS IVA), Naglazyme (MPS VI), Aldurazyme (MPS I, co-marketed with Genzyme), Brineura (CLN2), and Palynziq (PKU). Roctavian (gene therapy for hemophilia A) was approved but has faced commercial challenges. BioMarin has deep rare disease expertise across lysosomal storage disorders and metabolic diseases. | Alnylam is the pioneer of RNA interference (RNAi) therapeutics, with a commercial portfolio including Amvuttra (vutrisiran for hATTR), Onpattro (patisiran), Givlaari (givosiran for AHP), and Oxlumo (lumasiran for PH1). Leqvio (inclisiran for high cholesterol), licensed to Novartis, adds a large cardiovascular revenue stream. Alnylam's RNAi platform enables silencing of virtually any expressed gene, providing a broad modality applicable to genetic and common diseases alike. |
| Investor focus | Investors track enzyme replacement therapy revenue growth and durability, Roctavian hemophilia A gene therapy uptake, Voxzogo (achondroplasia) pediatric growth disorder revenue ramp, and overall revenue diversification beyond legacy ERT products. | Investors focus on Amvuttra quarterly revenue growth, Leqvio patient adoption milestones, pipeline programs in hypertension and complement disorders, and timeline to sustained GAAP profitability. |
BMRN strengths
- →Deep expertise in lysosomal storage disorders with multiple commercially approved ERTs and a dominant rare disease manufacturing capability
- →Voxzogo (vosoritide) for achondroplasia is a growing pediatric rare bone disorder franchise with global rollout potential
- →Long track record of navigating rare disease regulatory pathways and patient advocacy relationships enabling efficient launches
ALNY strengths
- →RNAi platform is a scientifically distinct drug modality with the ability to silence genes that small molecules or antibodies cannot target
- →Amvuttra's quarterly subcutaneous dosing is a significant convenience advantage over Onpattro's biweekly IV infusion for hATTR patients
- →Leqvio partnership with Novartis for lipid lowering expands Alnylam's commercial reach into mass-market cardiovascular without full commercial investment
Risks to watch — BMRN
- →Roctavian hemophilia A gene therapy has faced adoption challenges — reimbursement hurdles and competition from factor prophylaxis have limited uptake
- →ERT market maturity means existing products have limited organic growth — new product launches are essential for revenue re-acceleration
- →BioMarin's pipeline requires significant R&D investment to maintain the company's rare disease relevance beyond current product life cycles
Risks to watch — ALNY
- →Path to GAAP profitability requires Amvuttra reaching significant scale — currently still operating at a loss
- →hATTR market competition from Pfizer's Vyndamax/Vyndaqel (tafamidis stabilizers) and BridgeBio's acoramidis creates a competitive market
- →Pipeline programs in hypertension and complement are high value but years from potential approval
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →